Option chain shows key data for Indaptus Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Indaptus Therapeutics.

Indaptus Therapeutics (NASDAQ:INDP) Stock, Option Chain

Indaptus Therapeutics

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Tallinn,,Estonia,-,August,4th,2023,-,Screen,With,Stock

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CDTX

CMPS

INDP

LIPO

SANW

Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

Pre-Market Outlook

Movers

CTOR

DFLI

DHAI

EXEL

HUSA

MITQ

MRIN

Next Technology Holding Inc. - Ordinary Shares

NXTT

PCSA

RBNE

SISI

SQNS

SSII

TMDE

ZETA

Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket

Screenshot 2025-05-27 at 5.38.59 PM

Biotech

Reiteration

Indaptus Therapeutics Q1 Update: Company Advances Decoy20 Immunotherapy To Fight Cancer, Maxim Group Analyst Reiterates Buy Rating

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics Inc

Legal

Press Releases

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Registration Is Now Open For Tribe Public's Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Earnings

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Health Care

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Analyst Ratings

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Apollomics Inc. - Class A Ordinary Shares

Apollomics

180 Life Sciences

Azitra

Bone Biologics

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Galecto

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mustang Bio

Moleculin Biotech

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Polyrizon

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

SILO Pharma

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Xenetic Biosciences

Maxim Group

HC Wainwright & Co.

Screenshot 2025-04-21 at 5.37.26 PM

General

Bacteria: The Surprising Tool In The Fight Against Cancer – And How Indaptus Is Taking It Further

Screenshot 2025-03-17 at 5.34.34 PM

Aggressive Cancers In Young People Are On The Rise – Can The Immune System Fight Back Better? Indaptus Therapeutics Thinks So

Comments

Indaptus Therapeutics

Indaptus Therapeutics (INDP) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell